J2AZ34 Stock Overview Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Jazz Pharmaceuticals plc Competitors Price History & Performance
Summary of share price highs, lows and changes for Jazz Pharmaceuticals Historical stock prices Current Share Price US$40.48 52 Week High US$42.40 52 Week Low US$38.72 Beta 0.57 1 Month Change 0% 3 Month Change n/a 1 Year Change n/a 3 Year Change n/a 5 Year Change n/a Change since IPO -18.15%
Recent News & Updates Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Dec 17
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits Dec 07
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?) Dec 05
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Dec 03
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) Nov 21
Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia Nov 01 See more updates Bruce Cozadd to Retire as Chief Executive Officer of Jazz Pharmaceuticals plc Upon Appointment of Successor by the End of 2025 Dec 17
Jazz Pharmaceuticals plc to Showcase New Real-World Evidence Reinforcing Epidiolex (Cannabidiol) Benefits Dec 07
Jazz Pharmaceuticals plc Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Biliary Tract Cancers to Include Zanidatamab-Hrii (Ziihera®?) Dec 05
Jazz Pharmaceuticals plc to Present Advancements in Solid Tumors and Blood Cancer Research at San Antonio Breast Cancer Symposium and American Society of Hematology Annual Meeting Dec 03
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-Positive (IHC 3+) Biliary Tract Cancer (BTC) Nov 21
Jazz Pharmaceuticals plc Presents New Data at Psych Congress 2024 Confirming Xywav®? (Calcium, Potent, and Sodium Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia Nov 01
Jazz Pharmaceuticals plc to Report Q3, 2024 Results on Nov 06, 2024 Oct 24
Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (Lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Oct 15
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from FTSE All-World Index (USD) Sep 23
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024 Sep 16
gJazz Pharmaceuticals plc to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex/Epidyolex®? (Cannabidiol) At the European Epilepsy Congress 2024 Sep 05
Jazz Pharmaceuticals plc Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies Aug 23
Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares. Aug 02 Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) announces an Equity Buyback for $500 million worth of its shares. Aug 01
Jazz Pharmaceuticals plc Elect Laura Hamill to the Board of Directors Jul 26
Jazz Pharmaceuticals plc to Report Q2, 2024 Results on Jul 25, 2024 Jul 18
Jazz Pharmaceuticals plc Promotes Samantha Pearce to Chief Commercial Officer Jul 11
Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 2500 Growth Index Jul 03
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor Jun 20
Jazz Pharmaceuticals plc, Annual General Meeting, Jul 25, 2024 Jun 06
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board Jun 02
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024 May 31
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application (BLA) for Zanidatamab May 30
Jazz Pharmaceuticals plc Affirms Earnings Guidance for the Full Year 2024 May 02
Jazz Pharmaceuticals plc to Report Q1, 2024 Results on May 01, 2024 Apr 19
Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Apr 02
Jazz Pharmaceuticals plc Provides Earnings Guidance for the Full Year 2024 Feb 29
Jazz Pharmaceuticals Announces Board Changes Feb 27 Jazz Pharmaceuticals plc Appoints Philip Johnson as Executive Vice President, Effective March 1, 2024
Jazz Pharmaceuticals plc to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023 Dec 16
Jazz Pharmaceuticals plc to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Annual Meeting Dec 02
Jazz Pharmaceuticals plc to Report Q3, 2023 Results on Nov 08, 2023 Oct 26
Jazz Pharmaceuticals plc Presents Data Highlighting the Continued Need for Low-Sodium Treatment Option Xyw Oct 24
Jazz Pharmaceuticals plc to Present Data from Trials of Bispecific Antibody Zanidatamab and Zepzelca Oct 17
Jazz Pharmaceuticals plc Receives European Commission Approval for Enrylaze® for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Sep 22 Jazz Pharmaceuticals plc Announces Management Changes
Jazz Pharmaceuticals plc Revises Earnings Guidance for the Year 2023 Aug 10
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 30
Girard Sharp LLP and Motley Rice LLC Announce a Proposed Settlement in In re Xyrem (Sodium Oxybate) Antitrust Litigation Jul 29
Jazz Pharmaceuticals plc to Report Q2, 2023 Results on Aug 09, 2023 Jul 28
Jazz Pharmaceuticals plc, Annual General Meeting, Aug 03, 2023 Jun 17
Jazz Pharmaceuticals plc and Zymeworks Inc. Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers Jun 03
Jazz Pharmaceuticals plc Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023 Jun 01
Jazz Pharmaceuticals plc Affirms Revenue Guidance for the Year 2023 May 11
Jazz Pharmaceuticals plc to Report Q4, 2022 Results on Mar 01, 2023 Feb 16
Jazz Pharmaceuticals and Zymeworks Announces 84% Overall Survival At 18 Months from Phase 2 Trial Evaluating Zanidatamab in Her2-Expressing Metastatic Gastroesophageal Adenocarcinoma Jan 20
Jazz Pharmaceuticals Presents New Findings From Caregiver Survey on Outcomes of Epidiolex® (cannabidiol) for Adult and Pediatric Patients With Severe, Childhood-Onset Epilepsies Dec 06
Jazz Pharmaceuticals to Present Data Demonstrating Advancements in Epilepsy Outcomes At the 2022 American Epilepsy Society Annual Meeting Nov 29
Jazz Pharmaceuticals plc Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze® (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) Nov 19
Jazz Pharmaceuticals plc Raises Earnings Guidance for the Full Year 2022 Nov 10
Jazz Pharmaceuticals plc to Report Q3, 2022 Results on Nov 09, 2022 Oct 27
Jazz Pharmaceuticals plc Reiterates Revenue Guidance for the Full Year 2022 Sep 08
Jazz Pharmaceuticals Announces Initiation of Phase 3 Trial Evaluating Epidiolex Epidyolex (Cannabidiol) for Patients with Epilepsy with Myoclonic-Atonic Seizures Aug 19
Jazz Pharmaceuticals plc Updates Earnings Guidance for the Year 2022 Aug 04
Jazz Pharmaceuticals plc to Report Q2, 2022 Results on Aug 03, 2022 Jul 21
Jazz Pharmaceuticals Announces Top-line Results from Phase 3 Trial Evaluating Nabiximols Oromucosal Spray in Adult Participants with Multiple Sclerosis Spasticity Jun 29
Jazz Pharmaceuticals plc, Annual General Meeting, Jul 28, 2022 Jun 14
Jazz Pharmaceuticals plc Presents Positive Data from Phase 2/3 Trial of Rylaze (Asparaginase Erwinia Chrysanthemi (Recombinant)-Rywn) in Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma At the ASCO 2022 Annual Meeting Jun 08
Jazz Pharmaceuticals plc Raises Financial Guidance for the Full Year 2022 May 05
Jazz Pharmaceuticals plc to Report Q1, 2022 Results on May 04, 2022 Apr 21
Jazz Pharmaceuticals Presents Pre-Clinical Data for Pan-RAF Inhibitor JZP815, Including Pharmacokinetic Properties and Efficacy in Multiple Solid Tumor Types Apr 09
Axsome Therapeutics, Inc. (NasdaqGM:AXSM) agreed to acquire Sunosi® from Jazz Pharmaceuticals plc (NasdaqGS:JAZZ) for $53 million. Mar 29
Jazz Pharmaceuticals plc Provides Revenue Guidance for the Full Year 2022 Mar 03
Jazz Pharmaceuticals plc to Report Fiscal Year 2021 Results on Mar 01, 2022 Feb 16
Jazz Pharmaceuticals plc Completes U.S. FDA Supplemental Biologics License Application for Rylaze Feb 03 Shareholder Returns J2AZ34 BR Pharmaceuticals BR Market 7D 0% -3.4% -3.0% 1Y n/a -27.4% -11.7%
See full shareholder returns
Return vs Market: Insufficient data to determine how J2AZ34 performed against the BR Market .
Price Volatility Is J2AZ34's price volatile compared to industry and market? J2AZ34 volatility J2AZ34 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 6.6% Market Average Movement 5.1% 10% most volatile stocks in BR Market 9.5% 10% least volatile stocks in BR Market 2.8%
Stable Share Price: J2AZ34's share price has been volatile over the past 3 months compared to the BR market.
Volatility Over Time: Insufficient data to determine J2AZ34's volatility change over the past year.
About the Company Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders.
Show more Jazz Pharmaceuticals plc Fundamentals Summary How do Jazz Pharmaceuticals's earnings and revenue compare to its market cap? J2AZ34 fundamental statistics Market cap R$45.24b Earnings (TTM ) R$2.82b Revenue (TTM ) R$24.29b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) J2AZ34 income statement (TTM ) Revenue US$3.99b Cost of Revenue US$294.67m Gross Profit US$3.70b Other Expenses US$3.23b Earnings US$463.16m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) 7.66 Gross Margin 92.62% Net Profit Margin 11.60% Debt/Equity Ratio 146.6%
How did J2AZ34 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 09:31 End of Day Share Price 2024/09/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Jazz Pharmaceuticals plc is covered by 51 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Joel Beatty Baird Ishan Majumdar Baptista Research Richard Silver Barclays
Show 48 more analysts 